期刊文献+

不同透析方式对尿毒症患者心脏结构的影响 被引量:4

Different Effects of Two Dialysis Methods on Cardiac Structure in Patients with Uremia
下载PDF
导出
摘要 目的:比较血液透析(hemodialysis,HD)与腹膜透析(peritoneal dialysis,PD)治疗对尿毒症患者心脏结构的影响。方法:选择我院住院诊断为尿毒症的患者42例,随机分为血液透析组和腹膜透析组各21例,分别于透析治疗后1个月及透析后6个月行心脏彩色多普勒检查,测量常规指标:左心房内径(LA)、左室舒张末径(LVEDd)、左室后壁舒张末厚度(LVPWd)、室间隔舒张末厚度(IVSd)。结果:血液透析及腹膜透析治疗1个月后较透析前LA、LVEDd、IVSd及LVPWd有明显减小(P<0.05),6个月后LA、LVEDd、IVSd及LVPWd较1个月时亦有所减小(P<0.05);透析治疗1个月及6个月后腹膜透析组对心脏结构改善均明显优于血液透析组(P<0.05)。结论:腹膜透析及血液透析均能改善尿毒症患者的心脏结构,而腹膜透析效果更优于血液透析,随着透析时间延长,心脏结构改善更明显。 Objective: To compare the impacts of hemodialysis with peritoneal dialysis on cardiac structure in patients with uremia. Methods: 42 cases with uremia in our hospital were randomly divided into hemodialysis group( HD group) and peritoneal dialysis group( PD group) with 21 cases in each. After a month and six months of dialysis,the cardiac color Doppler examination was performed to measure conventional indicators: left atrial diameter( LA),left ventricular end-diastolic diameter( LVEDd),left ventricular end-diastolic posterior wall depth( LVPWd),interventricular end-diastolic septal diameter( IVSd). Results: LA,LVEDd,IVSd and LVPWd one month after hemodialysis and peritoneal dialysis reduced significantly compared with those before dialysis( P < 0. 05); the above indicators after six months were lower than those after one month( P < 0. 05); the cardiac structure in PD group was significantly better than that in HD group after a month and six months( P < 0. 05). Conclusion:Hemodialysis and peritoneal dialysis can improve cardiac structure of uremic patients,and peritoneal dialysis is more effective than hemodialysis. The cardiac structure is improved more with the dialysis time duration.
出处 《现代临床医学》 2016年第3期188-189,192,共3页 Journal of Modern Clinical Medicine
关键词 血液透析 腹膜透析 尿毒症心肌病 慢性肾衰竭 hemodialysis peritoneal dialysis uremic cardiomyopathy chronic renal failure
  • 相关文献

参考文献8

二级参考文献75

  • 1汪涛.腹膜透析的现状和展望[J].中国实用内科杂志:临床前沿版,2006,26(1):92-95. 被引量:36
  • 2Weidtmann B, Schunkert H. Uremia and cardiovascular disease. Internist, 2007 ; 48 (8) : 770 - 778
  • 3Mall G. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant, 1990; 5:39 -44
  • 4Gross ML, Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia - - beyond coronary heart disease. Semin Dial, 2008; 21 (4): 308-318
  • 5Amann K, Buzello M, Simonnaviciene A. Capillary/myocyle mismatch in the heart in renal failure - a role for erythropoietin ? Nephrol Dial Transplant, 2000; 15 (7) : 96
  • 6Ansari , Vemejoui MC, Fabiani F. Secondary hypertrophy in hemodialysis patients. Kidney Int, 1997; 32 -33
  • 7Nayak SG, Satisk R. An unusual toxic cause of hemolytic -uremic syndrome. J Toxicol Sci, 2007, 32 (2) : 197 - 199
  • 8Amann K, Ritz E, Wiest Get al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J An See Mphml, 1994; 4 (10) : 1814-1819
  • 9Hara S, Ubara Y, Arimno K. Relation between parathyroid hormone and cardiac function in long - term hemodialysis patients. Miner Electrolyte Nbtab, 1995; 21 ( 1 - 3) : 72 - 76
  • 10Paolo R, Boulay A, Chasan - Taber Set al. Cardiac calcification in adult hemodialysis patients: A link between end - stage renal disase and cardiovascular disease. J Am Call Cardiol, 2002; 39 (4): 695- 701

共引文献42

同被引文献20

引证文献4

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部